RE:RE:RE:RE:RE:RE:RE:RE:SPCEO1?smartmichel wrote: jfm1330 wrote: Sorry. All that was supposed to follow approval news. 3rd an 4th drug do not grow on tress. You normally need money to acquire rights. Thera was supposed to buy these rights with the money from Ibalizumab, Forget about Europe. Pointless to talk about it if we cannot get Ibalizumab approved in the US. Same for NASDAQ. Same for pricing. All but the F4 is linked to approval and again, the problem with that is not on Thera, but on Taimed. They are the sponsor of Ibalizumab. They need to get the job done. Thera has very little power on that process. As us they are passengers.
No Sir. With respect, Thera bought Ibalizumab with $1M for a potential $1B sales. If you have your high school degree in maths, you can have an idea of the cash down for a $100 million sales drug. You forget TH has now 31 sales reps on the ground + $30M cash on hands + TH money (shares) at $5.50 CAD tomorrow. A very atractive situation for a licence deal.
If you are logical, TH can't go foward and grow if Ibalizumab will fail and TH must stay motionless to avoid distraction? The business minding is clear: Add a 3rd drug or fire 20 sales reps and their managers, Now.
I don’t think it would be a good idea to fire all the new sales reps and their managers for a delay.
That would take away from any inroads they have already made with influential ID docs in the US.
I suppose some could be dropped but there is no way they fire all of them unless there is a major issue with the application (rather than a technicality)
bfw